Crossmark

Safety, Tolerability, and Pharmacokinetics of the Monoamine Oxidase B Inhibitor, HEC122505, and its Major Metabolite After Single- and Multiple- Ascending Dose, and Food Effect Study in Healthy Chinese Subjects

Crossref DOI link: https://doi.org/10.1007/s13318-024-00880-w

Published Online: 2024-03-06

Published Print: 2024-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jin, Chuanfei https://orcid.org/0000-0002-0024-9530
Yi, Chao

Chen, Kangzhi

Liang, Haiping
License Information

Text and Data Mining valid from 2024-03-06

Version of Record valid from 2024-03-06
More Information

Article History

Accepted: 17 January 2024

First Online: 6 March 2024

Conflict of interest

: All authors are employees of HEC Pharm Group and Sunshine Lake Pharma Co., Ltd.

: The studies were designed and conducted at a clinical research center in China, in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines. Prior to study initiation, the clinical trial protocol, and case report form (CRF), informed consent form and other clinical study documents were approved by the Ethics Committee of Shanghai Xuhui District Central Hospital. The clinical trial was registered at (registration No. CTR 20202198, registration date: 10/Nov/2022).

: All subject gave written informed consent to participate in the studies.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below